Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.


Click here to select your areas of interest

Areas of interest

Select to filter on program types

E-learnings, Meet the author 06/07/2020

Meet the Author: prof. Brian Rini and prof. Toni Choueiri

In this e-learning, authors prof. Brian Rini and prof. Toni Choueiri. will be queried by a panel of fellow oncologists about the recent results of the Keynote-426 and Javelin 101 Renal studies.   In both phase III trials, the combination of an immunotherapy agent with the tyrosine kinase inhibitor axitinib was compared to sunitinib as first line treatment of advanced renal cell carcinoma. The panel of experts, led by prof. John Haanen, will thoroughly discuss the results of these trials with both authors.  This program provides the opportunity to gain detailed knowledge of the Keynote-426 en Javelin 101 Renal trials. Together with the authors, the expert panel will offer profound insight into the setup and execution of both trials. They will discuss the different results and assess their impact on daily clinical practice. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. Motzer RJ, Penkov K, Haanen J et al. N Engl J Med 2019; 380:1103-1115. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. Rini BI, Plimack ER, Stus V, et al. N Engl J Med 2019; 380:1116-1127. Authors Prof. Brian Rini, MD - medical oncologist, Vanderbilt-Ingram Cancer Center, Nashville, US; prof. Toni Choueiri, MD - medical oncologist, Dana-Farber Cancer Institute, Boston, US. Discussion panel Prof. John Haanen, MD, PhD - medical oncologist NKI-AvL, Amsterdam; Axel Bex, MD, PhD - urologic surgeon, Royal Free Hospital, London, UK; Sjoukje Oosting, MD, PhD - medical oncologist, UMCG, Groningen.

Congress news 22/06/2020

ASCO Discussion Round III: Highlights from a European Perspective

In this third live discussion round, experts from Switzerland and Germany discuss practice-changing studies in the fields of GU, Immunoncology and Hematology with the ASCO2020 original authors.  The following authors are presenting their studies:  Dr. Thierry André Sorbonne University and Saint-Antoine Hospital, Paris, France Pembrolizumab Versus Chemotherapy for Microsatellite Instability-High/Mismatch Repair Deficient Metastatic Colorectal Cancer: The Phase 3 KEYNOTE-177 Study   Prof. Dr. Shaji Kumar Mayo Clinic, Rochester, MN, USA Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial.   Dr. Landon Carter Brown Duke Cancer Institute, Durham, North Carolina, USA Association of LRP1B pathogenic genomic alterations with favorable outcomes with immune checkpoint inhibitors across multiple tumor types.   Dr. Jesus G. Berdeja Sarah Cannon Research Institute, Nashville, TN, USA Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma.   Prof. Dr. Thomas Powles Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, London, UK Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis.   ASCO DirectTM is a multi-sponsoring project and one of the American Society of Clinical Oncology® (ASCO®) licensed services.

Congress news 22/06/2020

ASCO Discussion Round I: Highlights from a European Perspective

In this discussion, round experts from Switzerland and Germany discuss practice-changing studies with the ASCO2020 original authors.  The following authors are presenting their studies:    Dr. Fatima Cardoso         Breast Cancer Unit, Champalimaud Cancer Center, Lisbon, Portugal MINDACT: Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients   Dr. Javier Cortes Breast Cancer Program, IOB Institute of Oncology, Madrid & Barcelona, Spain                      KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.   Prof. Dr. Andreas du Bois Department Gynecology & Gyn.Oncology KEM, Evang. Kliniken Essen-Mitte gGmbH, Essen, Germany Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: Final analysis of AGO DESKTOP III/ENGOT-ov20.   ASCO DirectTM is a multi-sponsoring project and one of the American Society of Clinical Oncology® (ASCO®) licensed services.

Congress news 22/06/2020

ASCO Discussion Round II: Highlights from a European Perspective

In this second round table discussion, experts from Switzerland and Germany discuss practice-changing studies in the fields of Head & Neck Tumors and Lung Cancer with the ASCO2020 original authors.  The following authors are presenting their studies:  Prof. Dr. Kevin Joseph Harrington The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust National Institute of Health Research Biomedical Research Centre, London, United Kingdom KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).            Prof. Dr. Martin Reck LungenClinic Grosshansdorf, Grosshansdorf, Germany Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA.   Prof. Dr. Joel Guigay                 Centre Antoine Lacassagne, FHU OncoAge, Université Côte d'Azur, France TPExtreme randomized trial: Quality of Life (QoL) and survival according to second-line treatments in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).   John Kuruvilla, MD (Dr.) Princess Margaret Cancer Centre, Toronto, ON, Canada KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL).   ASCO DirectTM is a multi-sponsoring project and one of the American Society of Clinical Oncology® (ASCO®) licensed services.

E-learnings 21/01/2020

Treatment of advanced melanoma

Over the last decade, the treatment of advanced melanoma has been significantly changed with the development of targeted therapy and immunotherapy. Now, we finally have five-year survival data for both kinds of treatments. How do these results impact daily clinical practice? MEDtalks brings you an on demand e-learning (recorded on January 21st, 2020), in which a Belgian expert panel discusses first and second line treatment of advanced melanoma with targeted therapy and immunotherapy. Furthermore, the burning question on everybody’s mind after the presentation of the five-year survival results of the CheckMate 067 trial is of course not left untouched: should patients be treated with combination immunotherapy or monotherapy? And besides this systemic armamentarium, what is the role of local treatment options in the current treatment of (brain) metastasized melanoma? Panel members Prof. Bart Neyns, MD, PhD - medical oncologist, University Hospital of Brussels Prof. Vibeke Kruse, MD, PhD - medical oncologist, Ghent University Annemie Rutten, MD, PhD - medical oncologist, GZA Hospital Sint-Augustinus Prof. Dirk van Gestel, MD, PhD - radiation oncologist, Institut Jules Bordet Subjects (among others) Five-year survival rate of targeted therapy and immunotherapy;   First and second line systemic treatment of advanced melanoma; Combination immunotherapy versus monotherapy anti-PD1 subsequently followed by anti-CTLA4; Management of patients with poor prognostic factors (e.g. brain metastases) with both systemic and local therapy. This e-learning is accredited for Dutch oncologists (1 CME point). We are requesting accreditation for medical oncologists in Belgium. Points are credited as soon as accreditation has been granted.

Congress news 23/11/2019

SMR 2019: Grant McArthur

It was already clear that the BRAF/MEK-combination cobimetinib + vemurafenib performs better then vemurafenib + placebo in terms of efficacy. On the SMR 2019 five-year survival results were presented. Prof. Grant McArthur talks you through the efficacy and toxicity and discusses the significance of these new data on daily clinical practice.

Congress news 23/11/2019

SMR 2019: Peter Lau

Peter Lau has examined the efficacy of second line treatment of brain metastasis with the combination ipilimumab and nivolumab after progression on targeted therapy and will present this data.

Congress news 23/11/2019

SMR 2019: Pier Ferrucci

There are a couple of ongoing trials examining the combination of immunotherapy and targeted therapy. One of them is the KEYNOTE-022 trial. Dr. Pier Francesco Ferrucci comments on the efficacy and toxicity of the combination of pembrolizumab, dabrafenib and trametinib in comparison to dabrafenib, trametinib and placebo.

Congress news 23/11/2019

SMR 2019: Mitchell Fane

Mitchell Fane talks about his research of changes in the microenvironment and the immune system that create a permissive niche for metastatic outgrowth of melanoma cells in the lung. These changes occur in the elderly patient. He will expand on what this means for further research.

Congress news 23/11/2019

SMR 2019: Eva Perez

Eva Perez-Guijarro, PhD, explains how preclinical mouse models in the National Cancer Institute are used to predict the response of immunotherapy and to identify new predictive biomarkers. Human clinical datasets are used to validate these potential biomarkers.

Congress news 23/11/2019

SMR 2019: Sean Morrison

Recent research shows that oxidative stress lowers the chance of metastasizing. When comparing a group of patients taking high doses of antioxidants to a control group, the former perform less in terms of survival. Prof. Sean Morrison’s lab examines the pathways that lead to declined sensitivity of melanoma cells to oxidative stress, as well as methods to inhibit those pathways to lower the chance of metastasis.